Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

212 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Drotrecogin alfa (activated) in adults with septic shock.
Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gårdlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD; PROWESS-SHOCK Study Group. Ranieri VM, et al. Among authors: dhainaut jf. N Engl J Med. 2012 May 31;366(22):2055-64. doi: 10.1056/NEJMoa1202290. Epub 2012 May 22. N Engl J Med. 2012. PMID: 22616830 Free article. Clinical Trial.
Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.
Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, Artigas A, Fumagalli R, Macias W, Wright T, Wong K, Sundin DP, Turlo MA, Janes J. Vincent JL, et al. Among authors: dhainaut jf. Crit Care Med. 2005 Oct;33(10):2266-77. doi: 10.1097/01.ccm.0000181729.46010.83. Crit Care Med. 2005. PMID: 16215381 Clinical Trial.
Statistical analysis plan of PROWESS SHOCK study.
PROWESS SHOCK Steering Committee; Thompson BT, Ranieri VM, Finfer S, Barie PS, Dhainaut JF, Douglas IS, Gårdlund B, Marshall JC, Rhodes A. PROWESS SHOCK Steering Committee, et al. Among authors: dhainaut jf. Intensive Care Med. 2010 Nov;36(11):1972-3. doi: 10.1007/s00134-010-1977-3. Epub 2010 Aug 6. Intensive Care Med. 2010. PMID: 20689934 Free PMC article. No abstract available.
Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial.
Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, Riess H, Basson BR, Charpentier J, Utterback BG, Vincent JL; Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Dhainaut JF, et al. Intensive Care Med. 2003 Jun;29(6):894-903. doi: 10.1007/s00134-003-1731-1. Epub 2003 Apr 24. Intensive Care Med. 2003. PMID: 12712239 Clinical Trial.
Unblinding plan of PROWESS-SHOCK trial.
Ranieri VM, Thompson BT, Finfer S, Barie PS, Dhainaut JF, Douglas IS, Gårdlund B, Marshall JC, Rhodes A; PROWESS-SHOCK Academic Steering Committee. Ranieri VM, et al. Among authors: dhainaut jf. Intensive Care Med. 2011 Aug;37(8):1384-5. doi: 10.1007/s00134-011-2272-7. Epub 2011 Jun 21. Intensive Care Med. 2011. PMID: 21691888 No abstract available.
212 results